Advertisement
U.S. markets closed
Advertisement

Bureau Veritas SA (BVVBY)

Other OTC - Other OTC Delayed Price. Currency in USD
48.39+0.10 (+0.21%)
At close: 02:56PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close48.29
Open48.06
BidN/A x N/A
AskN/A x N/A
Day's Range47.99 - 48.56
52 Week Range44.55 - 59.09
Volume8,841
Avg. Volume17,200
Market Cap11.053B
Beta (5Y Monthly)0.92
PE Ratio (TTM)21.41
EPS (TTM)2.26
Earnings DateN/A
Forward Dividend & Yield1.68 (3.46%)
Ex-Dividend DateJul 03, 2023
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for BVVBY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BUREAU VERITAS UNSPON ADR EACH
    Analyst Report: Merck KGaAMerck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (47% of 2022 sales) primarily provides laboratory consumables and services to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (35%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (18%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
    Rating
    Fair Value
    Economic Moat
    12 days agoMorningstar
View more
  • GlobeNewswire

    BUREAU VERITAS - Number of shares and voting rights as of October 31, 2023

    REGULATED INFORMATION Neuilly-sur-Seine, France – November 22, 2023 Information on number of shares and voting rights as stipulated by article 223-16 of the general regulations of the French financial markets authority AMF Issuer: Bureau Veritas DateNumber of shares(1)Number of voting rights31/10/2023453,871,520Theoretical number of voting rights: 624,035,005Number of exercisable voting rights: 623,766,797 (1) including the new shares issued in Euroclear as a result of the exercise of stock opti

  • GlobeNewswire

    BUREAU VERITAS - Solid organic revenue growth in the third quarter; 2023 outlook confirmed

    PRESS RELEASE Neuilly-sur-Seine, France – October 25, 2023 Solid organic revenue growth in the third quarter;2023 outlook confirmed Q3 2023 Key Figures1 Revenue of EUR 1,423.8 million in the third quarter of 2023, up 6.1% at constant currency, of which 5.8% organic Strong organic growth from Marine & Offshore +13.4%, Industry +16.2% and Certification +11.7% compared to the third quarter of 2022; growth of +2.6% for Agri-Food & Commodities; and flat organic growth for both Buildings & Infrastruct

  • GlobeNewswire

    BUREAU VERITAS - Number of shares and voting rights as of September 30, 2023

    REGULATED INFORMATION Neuilly-sur-Seine, France – October 17, 2023 Information on number of shares and voting rights as stipulated by article 223-16 of the general regulations of the French financial markets authority AMF Issuer: Bureau Veritas DateNumber of shares(1)Number of voting rights30/09/2023453,871,520Theoretical number of voting rights: 624,035,211Number of exercisable voting rights: 623,772,560 (1) including the new shares issued in Euroclear as a result of the exercise of stock optio